Medartis (MED.SW) up 6.42% on SIX 17 Mar 2026: price targets and outlook

MED.SW stock closed the Swiss session at CHF84.60, up 6.42% on SIX on 17 Mar 2026 after a market-moving update. Volume reached 4,788.00, above the 50-day average, and the intraday range was CHF82.00–85.80. The rally places Medartis Holding AG in the top gainers on the Swiss market today. We examine the drivers behind the move, the company’s financials, key ratios, technical set-up and what Meyka AI’s forecast implies for traders and investors.

Price action and catalysts for MED.SW stock

Medartis (MED.SW) closed at CHF84.60, a CHF5.10 gain, or 6.42%, from the previous close of CHF79.50. The stock traded between CHF82.00 and CHF85.80 on volume of 4,788.00, slightly above average volume of 4,439.00. Today’s move ranks MED.SW among the top gainers on SIX and reflects fresh investor interest after the company’s update and higher-than-normal buying pressure.

The immediate catalyst appears company-level news and reaction to the earnings-announcement timing. Market participants noted Medartis’ steady revenue per share and healthy cash buffers, which supported the short-term rally in the medical devices sector.

Earnings, cash position and recent financials

Medartis reported trailing EPS of -0.05 and a reported PE of -1672.00, driven by a small net loss. Revenue per share stands at 19.56 and operating cash flow per share is 2.28. The company holds CHF9.97 cash per share and book value per share of CHF21.62, supporting the balance sheet narrative.

Free cash flow per share is 1.61 and the current ratio is 5.31, indicating strong short-term liquidity. These cash metrics likely reinforced buyer confidence during today’s session despite the negative EPS.

Valuation and sector comparison for MED.SW stock

MED.SW’s price-to-sales ratio is 4.40 and price-to-book is 3.87, close to healthcare peers on PB but above the broader sector P/S averages. The Healthcare sector average PE is 29.45, while Medartis’ PE remains negative. Enterprise value to sales is 4.41 and EV/EBITDA is 29.47, which implies a premium valuation versus some medical-device peers.

Inventory turnover and working capital are notable: days of inventory on hand are 641.96, which is unusually high. That long inventory cycle is a structural metric investors should monitor when valuing MED.SW stock versus medical-device comparables.

Technical picture and trading signals

Technically, MED.SW shows momentum on a rebound but still lacks trend confirmation. RSI sits at 35.27, below neutral territory, and MACD histogram is negative at -1.14. Bollinger Bands middle is 88.71 and lower band is 80.24, so today’s close at CHF84.60 sits between the middle and lower band.

On balance, the short-term bias is recovery within a broader sideways range. Traders may watch a break above the 50-day average of CHF89.43 and the 200-day average of CHF84.35 for trend confirmation, with ATR at 4.10 signalling moderate volatility.

Meyka AI rates MED.SW with a score out of 100

Meyka AI rates MED.SW with a score out of 100. Score: 73.66 | Grade: B+ | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade balances healthy cash metrics and free cash flow against negative EPS and long inventory days.

DISCLAIMER: These grades are not guaranteed and we are not financial advisors.

Meyka AI forecast, price targets and outlook

Meyka AI’s forecast model projects a yearly target of CHF83.63 and a quarterly projection of CHF98.37. Relative to today’s close at CHF84.60, the yearly projection implies -1.17% downside and the quarterly projection implies +16.27% upside. Forecasts are model-based projections and not guarantees.

Analyst-style view: a near-term upside target around CHF98.37 would require margin improvement and lower inventory days. A conservative scenario holds MED.SW near the model yearly level around CHF83.63.

Final Thoughts

Medartis (MED.SW) finished the Swiss session on 17 Mar 2026 at CHF84.60, up 6.42%, making it one of today’s top gainers on SIX. The move reflects investor focus on balance-sheet strength — cash per share CHF9.97 and current ratio 5.31 — despite a small trailing EPS loss of -0.05. Valuation is mixed: P/S of 4.40 and P/B of 3.87 sit near peers, while negative PE and long inventory days remain concerns. Technically, RSI 35.27 and MACD histogram -1.14 point to a rebound that still needs trend confirmation above the 50-day average CHF89.43. Meyka AI’s forecast model projects a yearly level of CHF83.63, implying -1.17% from the last price, and a quarterly target of CHF98.37, implying +16.27%. Investors should weigh the model projections, Medartis’ strong liquidity, and sector dynamics before positioning. Meyka AI’s analysis is part of our AI-powered market analysis platform and is model-based, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.